Insmed: Specialist in Lung Diseases Aims to Increase Patient Reach by a Factor of 80 by 2030 - Brensocatib Represents an $8.2 Billion Opportunity!

The biotech company Insmed (INSM) specializes in the treatment of rare and severe lung diseases. The core product is currently ARIKAYCE (liposomal amikacin for inhalation), which is used as an antibiotic with the active ingredient amikacin for the treatment of refractory lung infections caused by the Mycobacterium avium complex (MAC). ARIKAYCE is the first and only medication approved by the FDA for the treatment of MAC-related lung disease in adults, for which there are few or no alternatives. The target group currently comprises a manageable 30,000...